bit.bio expands Board of Directors with the Appointment of Entrepreneurs and a Nobel Laureate
bit.bio has appointed three new directors to its board, aiming to leverage their expertise to enhance its synthetic biology cell programming technology. Dr. Hermann Hauser becomes chair of the board, bringing extensive experience from founding Arm Ltd and Solexa. Sir Gregory Winter, a Nobel prize-winning scientist, joins to bolster therapeutic applications using human cells. Alan S. Roemer, an accomplished biotechnology entrepreneur, will support capital markets and operational growth strategies. Collectively, these leaders are expected to drive bit.bio's mission in transforming healthcare.
- Expertise of new board members in synthetic biology and biotechnology could enhance bit.bio's strategic direction.
- Hermann Hauser's leadership may attract investment and foster innovation in synthetic biology.
- Potential for new products and solutions based on human cells to transform healthcare and drug discovery.
- Concerns about continuity as new directors may present experience gaps in the current leadership.
- Challenges in executing the ambitious growth and innovation objectives laid out by new board members.
-
Dr
Hermann Hauser , serial entrepreneur, co-founder ofAmadeus Capital Partners and founder of semiconductor company,Arm Ltd , and gene-sequencing company,Solexa / Illumina, joins as chair of the board. -
Sir
Greg Winter ,Nobel -winning scientist, and known for his work on monoclonal antibodies, is the founder of multiple successful biotech companies. -
Alan S. Roemer , biotechnology entrepreneur who launched Pharmasset and Roivant Sciences, has raised over in private and public capital and consummated five IPOs.$1.75 billion
bit.bio's three new board members. (Photo: Business Wire)
“I believe bit.bio is well positioned to become one of the defining companies in the synthetic biology field, and I am very excited to take the position of chair of the board. I see world changing potential in their technology and look forward to bringing my experience and expertise to the leadership team. I want to see bit.bio grow into an iconic
Sir
Sir
“I think we are still in the foothills when it comes to the use of human cells for therapeutic applications, and I am excited to join bit.bio on their journey to the peaks. With access to potentially unlimited numbers of human cells at defined states of differentiation, we could do so much more for patients - whether researching difficult to treat, complex diseases, screening potential drugs on human cells, or developing precision cell therapies at an affordable cost. And the opti-ox technology seems to offer a realistic path to scale those peaks.”
"bit.bio is at that exciting stage of growth and evolution that I have been through several times before. It fuels my entrepreneurial spirit with the ‘fun factor’ of company expansion and cultural impact. I am excited to help the leadership team ‘see around corners’ using my experience from my other high-growth companies. Most importantly, I want to provide meaningful guidance to finance and scale the business, exploit the full potential of bit.bio’s core technology and have the potential to positively impact patients' lives.”
“I’m humbled to be bringing together three world leaders in science, entrepreneurship and industry making for the board of bit.bio. The expertise and experience our new board will bring to the company will give our technology the best chance to transform healthcare for every patient, everywhere.”
- ENDS -
About bit.bio
Accelerated biomedical research, new generations of cures, increased global sustainability. These are in reach when biology transitions to engineering.
At bit.bio, we work relentlessly to achieve this goal. We combine the concepts of coding and biology to provide human cells for research, drug discovery, and a new generation of medicines.
For more information visit bit.bio
View source version on businesswire.com: https://www.businesswire.com/news/home/20211028005473/en/
bitbio@aprilsix.com
+44 7875 468942
Source: bit.bio
FAQ
Who are the new board members of bit.bio?
What is the role of Hermann Hauser at bit.bio?
How does Alan S. Roemer plan to impact bit.bio?
What advancements are anticipated with the new board at bit.bio?